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Abstract
Dicopper(II) tetrakis(3,5-diisopropylsalicylate), (Cu(II)2(3,5-DIPS)4, manganese(II)
is(3,5-diisopropylsalicylate), Mn(II)(3,5-DIPS)) or combinations of them were used to treat
gamma-irradatedmice in examining the poss[6ility that combination treatments might_ be
more effective in increasing surviva[than treatment with either complex alone. Doses of 0,
10, 20, or 40 lamol of each complex per kilogram of body mass were administered
subcutaneously in a factorial design before 9 Gy gamma irradiation, an LD90 dose of irradiation.
Doses of 0, 10, 20, or 40 lamol Cu(II)(3,5-DIPS)4 per kg of body mass produced 12, 28, 28,
or 36 % survival, respectively, while doses of 0, 10, 20, or 40 #tool Mn(II)(3,5-DIPS)9 per kg
of body mass produced 12, 36, 20, or 24 % survival, respectively. However, the comfgination
of 20 lamol Cu(II)9(3,5-DIPS)4 and 10 ktmol Mn(II)(3,5-DIPS) produced the greatest survival,
48 %, which was-300 % greater than vehicle-treated mice (P=0.01). It is concluded that
specific combination treatments can be used to maximize survival of lethally irradiated mice.
Introduction
Both Cu(II)2(3,5-DIPS)4 and Mn(II)(3,5-DIPS)2 have been found to be effective
radioprotectants in LDs0/30 and LD00/30 radiation paradigms [1 and references therein]. Other
essential metalloelement compounds including chelates of zinc and iron have also been found
to have radioprotectant activity. It is suggested that the radioprotectant and radiorecovery
activity of various essential metalloelement compounds is based upon roles of these essential
metalloelement-dependent enzymes in repair of radiation injury [1].
Since essential metalloelement-dependent enzymes require a specific metalloelement(s)
for optimal activity, treatment with a single metalloelement will facilitate the role of that
class of metalloelement-dependent enzymes in responding to radiation injury and increasing
survival. A priori the response to overcome radiation injury by facilitating a single
metalloelement class of enzymes is limited. However, facilitating the response to radiation
injury by enhancing the activity of more than one class of essential metalloelement-dependent
enzymes should increase the effectiveness of treating radiation injury and increase survival.
In using either a single or multiple essential metalloelement treatment approach to
overcoming radiation injury there is plausible risk with regard to the incorporation of an
essential metalloelement into the wrong apoenzyme to yield a less active or inactive
metalloelement-dependent enzyme. Consequently, maximal effectiveness of this approach to
treatment may depend upon the use of a somewhat narrow range of combination doses.
We are reporting the radioprotectant activity (survival)of lethally irradiated mice
treated with Cu(II)2(3,5-DIPS)4, Mn(II)(3,5-DIPS)2, or combinations of these complexes.
The 900 Gy dose selected for these studies was chosen to increase radiation injury as a more
rigorous evaluation of combination treatlnents in providing radioprotectant activity.
Materials and Methods
The synthesis Cu(II)2(3,5-DIPS)4 and Mn(II)(3,5-DIPS) have been described in detail
[2]. Both compounds were first wetted with a volume of Propy-lene Glycol (Sigma) sufficient
to yield a final solution or suspension containing 4 % Propylene Glycol l’a 1.4 % of Polyvinyl
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Alcohol (Sigma # 1763) in Saline (Travenol). Incomplete vehicle, 1.4 % Polyvinyl Alcohol
in Saline, was prepared by dissolving 1.4g of Polyvinyl Alcohol in stirred Saline heated at 90C
for one hour. Complete vehicle was prepared by adding 4 ml of Propylene Glycol to 96 ml of
incomplete vehicle.
Three hundred and twenty l,tmol (341.1 mg) of Cu(II)(3,5-DIPS)4(H20)3, Mr 1,066
Daltons, was wetted with 4 ml of Propylene Glycol in a Potter-Elvehjem homogenizer while
cooling in an ice bath to prevent the increase in viscosity associated with homogenization
without cooling. The homogenate was then transferred to a 200 ml graduated cylnder with
sufficient incomplete vehicle to make 100 ml. The cylinder was covered with Parafilm
(American National Can) and vortex stirred to insure homogeneity. This suspension
containing 1.6 ]amol Cu(II)z(3,5-DIPS)4 per 0.5 ml was vortex stirred before all subsequent
usage.
Fifty ml of the 1.6 lamol/0.5 ml stirred suspension was diluted with 50 ml of complete
vehicle and the diluted 100 ml suspension vortex stirred. This suspension contained 0.8 mol
Cu(II)z(3,5-DIPS)4 per 0.5 ml. Treatment of a 20 g mouse with 0.5 ml of this suspension
provides 40 ktmol/kg of body mass.
Fifty ml of the 0.8 lamol/0.5 ml stirred suspension was diluted with 50 ml of complete
vehicle and the diluted 100 ml suspension vortex stirred. This suspension contained 0.4 ktmol
Cu(II)(3,5-DIPS)4 per 0.5 ml. Treatment of a 20 g mouse witti 0.5 ml of this suspension
provides 20 ktmol/kg of body mass.
Fifty ml of the 0.4 lamol/0.5 ml stirred suspension was diluted with 50 ml of complete
vehicle and the diluted 100 ml suspension vortex stirred. This suspension contained 0.2 mol
Cu(II)z(3,5-DIPS)4 per 0.5 ml. Treatment of a 20 g mouse witti 0.5 ml of this suspension
provides 10 ktmol/kg of body mass.
Three hundred and twenty lamol (168.3 rag) of Mn(II)(3,5-DIPS)z(HO) 5, Mr 526
Daltons, was wetted with 4 ml of Propylene Glycol in a Potter-Elvehjem homogenizer while
cooling in an ice bath to prevent the increase in viscosity associated with homogenization
without cooling. The homogenate was then transferred to a 200 ml graduated cylinder with
sufficient incomplete vehicle to make 100 ml. The cylinder was covered wth Parafilm
(American National Can) and vortex stirred to insure homogeneity of what appeared to be a
true solution. This apparent solution was still vortex stirred to guarantee homogeneity before
all subsequent dilutions. This solution contained 1.6 lamol Mn(II)(3,5-DIPS)z per 0.5 ml.
Fifty ml of the 1.6 lamol/0.5 ml stirred solution was diluted with 50 ml of complete
vehicle and the diluted 100 ml solution vortex stirred. This solution contained 0.8 lamol
Mn(II)(3,5-DIPS)2 per 0.5 ml. Treatment of a 20 g mouse with 0.5 ml of this suspension
provides 40 lamol/kg of body mass.
Fifty ml of the 0.8 tmol/0.5 ml stirred solution was diluted with 50 ml of complete
vehicle and the diluted 100 ml solution vortex stirred. This solution contained 0.4 lamol
Mn(II)(3,5-DIPS)2 per 0.5 ml. Treatment of a 20 g mouse with 0.5 ml of this suspension
provides 20 lmol/kg of body mass.
Fifty ml of the 0.4 lamol/0.5 ml stirred solution was diluted with 50 ml of complete
vehicle and the diluted 100 ml solution vortex stirred. This solution contained 0.2 lamol
Mn(II)(3,5-DIPS)2 per 0.5 ml. Treatment of a 20 g mouse with 0.5 ml of this suspension
provides 10 lamol/kg of body mass.
Ten ml of 0.4 lamol Cu(II)2(3,5-DIPS)4 suspension per 0.5 ml vortex stirred with 10 ml
of complete vehicle gave a 20 ml suspension containing 0.2 lamol Cu(II)2(3,5oDIPS)4 per 0.5
ml. Treatment of a 20 g mouse with 0.5 ml of this suspension provides 10 lamol Cu(I|)2(3,5-
DIPS) 4/kg of body mass.
Ten ml of 0.8 lamol Cu(II)2(3,5-DIPS)4 suspension per 0.5 ml vortex stirred with 10 ml
of_complete vehicle gave a 20 ml suspension containing 0.4 lamol Cu(II)2(3,5-DIPS)4 per 0.5
ml. Treatment of a 20 g mouse with 0.5 ml of this suspension provides 20 lamol Cu(II)2(3,5-
DIPS)4/kg of body mass.
Ten ml of 1.6 tmol Cu(II)2(3,5-DIPS)4 suspension per 0.5 ml vortex stirred with 10 ml
of’_complete vehicle gave a 20 ml Suspension containing 0.8 tmol Cu(II)2(3,5-DIPS)4 per 0.5
ml. Treatment of a 20 g mouse with 0.5 ml of this suspension provides 40 tmol Cu(II)2(3,5-
DIPS)4/kg of body mass.
Ten ml of 0.4 lamol Mn(II)(3,5-DIPS)2 suspension per 0.5 m vortex stirred with 10 ml
of complete vehicle gave a 20 ml Suspension containing 0.2 lamol Mn(II)(3,5-D!PS)2 per 0.5
ml. Treatment of a 20 g mouse with 0.5 ml of this suspension provides 10 lamol Mn(H)(3,5-
DIPS)2/kg of body mass.
Ten ml of 0.8 tmol Mn(II)(3,5-DIPS)2 suspension per 0.5 ml vortex stirred with 10 m!
of complete vehicle gave a 20 ml suspension containing 0.4 tmol Mn(II)(3,5-DIPS)2 per 0.5
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ml. Treatment of a 20 g mouse with 0.5 ml of this suspension provides 20 lamol Mn(II)(3,5-
DIPS)/kg of body mass.
Ten ml of 1.6 mol Mn(II)(3,5-DIPS)z suspension per 0.5 ml vortex stirred with 10 ml
of complete vehicle gave a 20 ml suspension containing 0.8 lamol Mn(II)(3,5-DIPS)2 per 0.5
ml. Treatment of a 20 g mouse with 0.5 ml of this suspension provides 40 lamol Mn(H)(3,5-
DIPS))_/kg of body mass.
Ten ml of 0.4 mol Cu(II)z(3,5-DIPS)4 suspension per 0.5 ml vortex stirred with 10 m|
of 0.4 lamol Mn(II)(3,5-DIPS) suspension per 0.5 ml gave a 20 ml suspension containing 0.2
lamol Cu(II)z(3,5-DIPS)4 and Mn(II)(3,5-DIPS) per 0.5 ml. Treatment of a 20 g mouse with
0.5 ml of ths suspension provides 10 lamol Cu(II)z(3,5-DIPS)4 and Mn(II)(3,5-DIPS))_/kg of
body mass.
Ten ml of 0.8 lamol Cu(II)z(3,5-DIPS)4 suspension per 0.5 ml vortex stirred with 10 ml
of 0.4 lumol Mn(II)(3,5-DIPS)z suspension per 0.5 ml gave a 20 ml suspension containing 0.4
lamol Cu(II)2(3,5-DIPS)4 and 0.2 lamol Mn(II)(3,5-DIPS)2 per 0.5 ml. Treatment _of a 20 g
mouse with 0.5 ml of this suspension provides 20 lamol Cu(II)2(3,5-DIPS)4 and 10 lumol
Mn(II)(3,5-DIPS)2/kg of body mass.
Ten ml of 1.6 lumol Cu(II)(3,5-DIPS)4 suspension per 0.5 ml vortex stirred with 10 ml
of 0.4 tmol Mn(II)(3,5-DIPS)2 suspension per 0.5 ml gave a 20 ml suspension containing 0.8
lamol Cu(II)z(3,5-DIPS)4 and 0.2 lamol Mn(II)(3,5-DIPS)) per 0.5 ml. Treatment of a 20 g
mouse with 0.5 ml of this suspension provides 40 lumol Cu(II)(3,5-DIPS)4 and 10 lumol
Mn(II)(3,5-DIPS)/kg of body mass.
Ten ml of 0.4 lamol Cu(II)(3,5-DIPS)4 suspension per 0.5 ml vortex stirred with 10 ml
of 0.8 lamol Mn(II)(3,5-DIPS) suspension per 0.5 ml gave a 20 ml suspension containing 0.2
lamol Cu(II))_(3,5-DIPS)4 and 0.4 lamol Mn(II)(3,5-DIPS) per 0.5 ml. Treatment of a 20 g
mouse with 0.5 ml of this suspension provides 10 lamol Cu(II)(3,5-DIPS)4 and 20 lamol
Mn(II)(3,5-DIPS)/kg of body mass.
Ten ml of 0.8 lumol Cu(II)(3,5-DIPS)4 suspension per 0.5 ml vortex stirred with 10 m!
of 0.8 lamol Mn(II)(3,5-DIPS)z suspension per 0.5 ml gave a 20 ml suspension containing 0.4
lamol Cu(II)z(3,5-DIPS)4 and 0.4 lumol Mn(II)(3,5-DIPS)z per 0.5 ml. Treatment of a 20 g
mouse with 0.5 ml of this suspension provides 20 lamol Cu(II)(3,5-DIPS)4 and Mn(II)(3,5-
DIPS)z/kg of body mass.
Ten ml of 1.6 lamol Cu(II)z(3,5-DIPS)4 suspension per 0.5 ml vortex stirred with 10 ml
of 0.8 lamol Mn(II)(3,5-DIPS)9 suspension per 0.5 ml gave a 20 ml suspension containing 0.8
lamol Cu(II)2(3,5-DIPS)4 and 0.4 mol Mn(II)(3,5-DIPS)2 per 0.5 ml. Treatment of a 20 g
mouse with 0.5 ml of this suspension provides 40 lamol Cu(II)2(3,5-DIPS)4 and 20 lamol
Mn(II)(3,5-DIPS)2/kg of body mass.
Ten ml of 0.4 lamol Cu(II)2(3,5-DIPS)4 suspension per 0.5 ml vortex stirred with 10 ml
of 1.6 lamol Mn(II)(3,5-DIPS)2 suspension per 0.5 ml gave a 20 ml suspension containing 0.2
lamol Cu(II)2(3,5-DIPS)4 and 0.8 lamol Mn(II)(3,5-DIPS)2 per 0.5 ml. Treatment of a 20 g
mouse with 0.5 ml of this suspension provides 10 lamol Cu(II)2(3,5-DIPS)4 and 40 lamol
Mn(II)(3,5-DIPS)2/kg of body mass.
Ten ml of 0.8 lamol Cu(II)2(3,5-DIPS)4 suspension per 0.5 ml vortex stirred with 10 ml
of 1.6 lumol Mn(II)(3,5-DIPS)2 suspension per 0.5 ml gave a 20 ml suspension containing 0.4
lamol Cu(II)2(3,5-DIPS)4 and 0.8 lamol Mn(II)(3,5-DIPS)2 per 0.5 ml. Treatment of a 20 g
mouse with 0.5 ml of this suspension provides 20 tmol Cu(II)2(3,5-DIPS)4 and 40 lamol
Mn(II)(3,5-DIPS)2/kg of body mass.
Ten ml of 1.6 lumol Cu(II)2(3,5-DIPS)4 suspension per 0.5 ml vortex stirred with 10 ml
of 1.6 lamol Mn(II)(3,5-DIPS)2 suspension per 0.5ml gave a 20 ml suspension containing 0.8
mol Cu(II)z(3,5-DIPS)4 and Mn(II)(3,5-DIPS)2 per 0.5 ml. Treatment of a 20 g mouse with
0.5 ml of ths suspension provides 40 lamol Cu(II)2(3,5-DIPS)4 and Mn(II)(3,5-DIPS)2/kg of
body mass.
These solutions were used to provide factorial design treatments shown in Table I.
Sixteen groups of 25 randomized 10 week old, young adult, 20 to 22 g female C57BL/6
mice housed 5 per cage, and fed mouse chow pellets and water ad libitum, with 12 hr light (6:00
am to 6:00 pm) and dark cycles for 3 weeks prior to treatment. Each group of 25 mice was
treated subcutaneously in the dorsal nape of the neck beginning at 9:00 am with one of the
sixteen treatments: either vehicle or one of the single or combination treatments, thr7 to
eight hours before gamma-irradiation (900 cGy, 124.5 cGy/min) in a Shepard Mark Cs
irradiator beginning at 12:00 pm. All 25 mice in each treatment group were irradiated over a
29 minute period and survivaldetermined over a 30 day post-treatment and irradiation period.
The 900 cGy dose was selected to increase radiation injury beyond the LD50/30 dose of800 c
Gy (1) to more rigorously examine these combination therapies for radioprotectant activity.
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Statistical comparisons of the proportion surviving among treatment groups were made
using Fisher’s Exact Test. The software used was StatXact-3 (Cytel Software Corporation).
All animal experiments were approved by the Institute’s Animal Care and Use
Committee which has an Animal Welfare Assurance on file with the Office of Protection from
Research Risks.
Results
As shown in Table I, treatment with all single and nearly all combination doses of
Cu(II)(3,5-DIPS)4 and/or Mn(II)(3,5-DIPS)z, were effective in increasing survival.
Treatment with 10 lamol, 20 lamol, or 40 lamol Cu(II)z(3,5-DIPS)4 gave survivals of 28 %, 28
%, or 36 %, respectively, as shown in Figure 1, which represent 133 %, 133 %, or 200 %
increases in survival compared vehicle-treated mice (Table II).
Table I. Percent survival of treated mice.
Micromole Mn(II)(3,5-DIPS)2
kg ofbod mass Micromole Cu(II 2(3,5-DIPS)4 k of body mass.
0 10 20 40
0 12" 28 28 36
,,b
10 36
a’b 36 "’ 48
,,v 36
.,t,
20 20 32 8 36
a,b
40 24 20 20 24
a. denotes a lack of statistically significant difference compared to the vehicle-treated group.
b. denotes a statistically significant difference from the 20 lamol Cu(II)z(3,5-DIPS)4 and 20 gmol
Mn(II)(3,5DIPS)z-treated group(p < 0.05), Fisher’s Exact Test.
c. denotes a statistically significant difference compared to the vehicle-treated group (p 0.01), Fisher’s Exact
Test.
Figure 1. Radioprotectant activity of vehicle (O), 10 gmol (), 20 li.tlnol (,), or 40 lumol
(’) Cu(II)(3,5-DIPS)4 per kg of body mass in 900 cGy irradiated mice.
Treatment with 10 lamol, 20 lamol, or 40 lamol Mn(II)(3,5-DIPS)z gave survivals of 36%,
20%, 24%, respectively, as shown in Figure 2, which represent 200%, 167%, or 100%
increases in survival compared to vehicle-treated mice (Table II).
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Table II. Percent increase in survival of complex-treated mice.
Micromole Mn(II)(3,5-DIPS)2
kg of body mass
0
10
20
40
Micromole Cu(II)(3r5-DIPS)4 kg of body mass.
0 10 20
133 133
200 200 300
67 167 -33
100 67 67
40
200
200
200
100
Figure 2. Radioprotectant activity of vehicle (O), 10 lamol (), 20 lamol (,), or 40 lamol
(’) Mn(II)(3,5-DIPS) per kg of body mass in 900 cGy irradiated mice.
Figure 3. Radioprotectant activity of vehicle (O), 10 lamol Cu(II)z(3,5-DIPS)4 and 10 lamol
Mn(II)(3,5-DIPS)z (), 10 l.tmol Cu(II)(3,5-DIPS)4 and 20 l.tmol Mn(II)(3,5-
DIPS) (&), or 10 lamol Cu(II)z(3,5-DIPS)4 and 40 tmol Mn(II)(3,5-DIPS) (’)
per kg of body mass in 900 cGy irradiated mice.
Nearly all treatments with combinations of Cu(II)(3,5-DIPS)4 and Mn(II)(3,5-DIPS)z
increased survival as shown in Figures 3, 4, and 5 with the exception of the 20 lamol
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Cu(II)2(3,5-DIPS)4 and Mn(II)(3,5-DIPS) /kg of body mass treatment shown in Figure 4.
These data show that addition of 10 gmol Mn(II)(3,5-DIPS)z to 10 lamol or 20 mol
Cu(II)z(3,5-DIPS)4 increased survival. The combination of 20 mol Cu(II)z(3,5-DIPS)4 and
10 lamol Mn(II)(3,5-DIPS)z /kg of body mass was most effective in increasing survival.
However, increasing the dose of Mn(II)(3,5-DIPS)z beyond 10 gmol/kg of body mass seems to
have decreased survival as shown in Tables I and II and the combination of 20 gmol
Cu(II)z(3,5-DIPS)4 and 20 lamol Mn(II)(3,5-DIPS)2 was ineffective in increasing survival.
Figure 4. Radioprotectant activity of vehicle (O), 20 lamol Cu(II)z(3,5-DIPS)4 and 10 lamol
Mn(II)(3,5-DIPS)z (), 20 gmol Cu(II)_(3,5-DIPS) and 20 lamol Mn(II)(3,5-DIPS)z (,), or
20 gmol Cu(II)z(3,5-DIPS)4 and 40 gmol Mn(II)(3,5-DIPS)z () per kg of body mass in 900
cGy irradiated mice.
Figure 5. Radioprotectant activity of vehicle (O), 40 gmol Cu(II)(3,5-DIPS).4 and 10 gmol
Mn(II)(3,5-DIPS)z (), 40 gmol Cu(II)z(3,5-DIPS)4 and 20 lamol Mn(II)(3,5-
DIPS)z (), or 40 gmol Cu(II)2(3,5-DIPS)4 and 40 lamol Mn(II)(3,5-DIPS)z (’)
per kg of body mass in 900 cGy irradiated mice.
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Discussion
None of the single or combination doses selected for this study caused acute toxicity,
death in a treatment group prior to death in the vehicle-treated group. As shown in Figures
to 5, there were no deaths in any group prior to day 5 after treatment.
Data presented in Tables and II and Figure show that treatment with Cu(II)z(3,5-
DIPS)4 caused an increase in survival in 900 cGy irradiated mice as the dose was increased from
10 lamol/kg to 40 lamol/kg with no change in survival when the dose was increased from 10
tmol/kg to 20 tmol/kg. Treatment with 10 lamol Mn(II)(3,5-DIPS)z/kg caused an increase in
survival compared with vehicle-treated mice. However, treatment with the higher doses, 20
lamol and 40 lamol/kg, did not cause a dose-related increase in survival which decreased with
increasing dose of Mn(II)(3,5-DIPS)z above 10 tmol/kg (Tables and II and Figures 2, 3, 4,
and 5). This decrease in survival may be due to a Mn-induced interference wherein Mn may be
inappropriately incorporated into an apoenzyme that requires some other essential
metalloelement to maximally fulfill its role in repair of a 900 cGy radiation injury. This
possible interference, which may arise with larger doses of irradiation, is offered as a rationale
in explaining why Mn(II)(3,5-DIPS) given to 800 cGy irradiated mice gave 100 % survival
[3]. The greater radiation injury caused by 900 cGy may have caused an increased essential
metalloelement-dependent response wherein there is an increased physiological response
involving other essential metalloelement-dependent enzymes that may be less active as a
result of the inappropriate incorporation of Mn.
This decrease in survival associated with increasing dose of Mn(II)(3,5-DIPS)2 from 10
lamol to 20 lamol, or 40 lamol/kg was also observed for all groups treated with Cu(II)2(3,5-
DIPS)4 and Mn(II)(3,5-DIPS) although this decrease was less severe when combination
treatment involved treatments with 40 lamol Cu(II):(3,5-DIPS)4/kg of body mass.
Groups of mice treated with 20 lamol Cu(II)(3,5-DIPS)4 and 20 tmol Mn(II)(3,5-
DIPS) had the lowest survival. Early in the course of this experiment, all mice in one cage
died on a single day following the determination of survival. Death of all mice in a single cage
is unusual in our experience, but may have been due to cannibalization of a mouse, that had
died as a result of pathogenic infection associated with irradiation-induced
immunoincompetence, by mice that were also immunoincompetent. If only one mouse would
have died in this group as a result of infection due to radiation-induced immunoincompetence
and there were no other deaths, survival for this group would have been 32 %, which is still less
than the 48 % survival for the group treated with 20 lamol Cu(II)_(3,5-DIPS)4 and 10 lamol
Mn(II)(3,5-DIPS)2/kg of body mass, and the consistent reduction in survival with increasing
dose of Mn(II)(3,5-DIPS)2 would still hold.
The maximal and statistically significant (P 0.01) increase in survival found for the 20
lamol Cu(II)2(3,5-DIPS)4 and 10 lamol Mn(II)(3,5-DIPS)2 combination treatment supports the
concept that treatment with a combination of metalloelement chelates provides a synergistic
increase in survival of lethally irradiated mice. It may also be biologically significant that the
ratio of Cu Mn in this combination treatment is 2 1, 40 lamol Cu and 20 tmol Mn since the
copper complex is binuclear and contains 2 atoms of copper while the manganese complex is
mononuclear and contains atom of manganese.
Acute toxicities for both the binulcear Cu(II)2(3,5-DIPS)4 and mononuclear Mn(II)(3,5-
DIPS)2 complexes have been reported to be 261 + 36 lamol/kg or 91 + 13 lamol/kg and 842 +
92 or 706 + 64 lamol/kg respectively for female or male C57BL/6 mice [1,2,9]. Both
complexes have been shown to increase survival in LDs0 mice at a dose of 49 to 80 lamol/kg of
body mass in female and male C57BL/6 mice when given subcutaneously or orally either up to
24 hrs before irradiation or up to 24 hrs after irradiation. The dose of irradiation for this
experiment was selected to approach the LD00 dose in order to more rigorously examine
combination therapy with regard to its potential in facilitating survival of mice experiencing
greater radiation injury. Results of these studies do support the possibility that combination
therapy does offer the potential for recovery from increased radiation injury.
In this study the treatment and irradiation intervals ranged from three to eight hours
starting with the control group and moving from left to right for the treatment groups shown
in Table and ending with the group treated with 40 lamol/kg Cu(II)2(3,5-DIPS)4 and
Mn(II)(3,5-DIPS)2/kg. This is not likely to have influenced the outcome of this experiment
67 67 since, as we have shown [7,8], Cu administered as Cu labeled Cu(II)2(3,5-DIPS)4 was
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conserved and remained in blood, liver, kidney, intestine, muscle, lung, thymus, femur, spleen,
and brain throughout the 5 day duration of our study. These complexes have also been found
to increase survival of LD0 irradiated mice when administered up to twenty-four hours before
irradiation. Data presented in Table II do not reveal an influence of time of treatment before
irradiation on survival. There were no statistically significant differences due to time of
irradiation following treatment. However, this point remains to be addressed in future
experiments when time before irradiation is held constant for all treatment groups.
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